Andy Miner
About Andy Miner
Andy Miner is the Associate Director of Policy Economics & Analytics at Bristol Myers Squibb, with over 15 years of experience in various roles within the company.
Company
Andy Miner currently serves as the Associate Director of Policy Economics & Analytics at Bristol Myers Squibb in Lawrenceville, NJ. He has accumulated over 15 years of experience in various roles within this leading biopharmaceutical company. His extensive background within Bristol Myers Squibb underscores his deep understanding of the company's operations and policies.
Title
Andy Miner holds the title of Associate Director, Policy Economics & Analytics at Bristol Myers Squibb. In this role, he contributes to strategic economic analyses and policy decision-making processes, leveraging his comprehensive knowledge acquired over many years within the company.
Previous Roles at Bristol Myers Squibb
Over his long tenure at Bristol Myers Squibb, Andy Miner has held multiple positions. From 2017 to 2019, he served as Manager of Government Contracts in Lawrenceville, NJ. Prior to that, he was Manager of Chargeback Operations in Tampa, FL from 2015 to 2017. He also worked as Associate Manager of Chargeback Operations in Plainsboro, NJ from 2010 to 2015. As a Senior Pricing & Reporting Analyst, he operated from 2008 to 2010, and he began his career at the company as a Chargeback Analyst from 2005 to 2008.
Education and Expertise
Andy Miner holds a BA in Liberal Arts from Bennington College, which he earned from 2002 to 2004. His educational background in liberal arts complements his professional activities, equipping him with a broad perspective and analytical skills applicable to his roles in policy economics, analytics, and government contract management.
Experience in Chargeback Operations
Andy Miner has extensive experience in chargeback operations, having held various positions in this area over a span of 10 years at Bristol Myers Squibb. His roles ranged from Chargeback Analyst to Manager, demonstrating a comprehensive understanding of chargeback processes and systems, pivotal to the financial operations of a biopharmaceutical company.